OU Health University of Oklahoma Medical Center

Oklahoma City, Oklahoma 73104

3 studies enrolling now · 4 studies all time

What they study most

Acquired Antithrombin Deficiency, Acute Major Bleeding, Carcinoma, Non-Small Cell Lung, Cutaneous Squamous Cell Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Exocrine Pancreatic Adenocarcinoma, Follicular Lymphoma (FL), Gastroesophageal Junction Adenocarcinoma, HER2 Negative Breast Neoplasms, Metastatic Castration Resistant Prostate Cancer (mCRPC), Ovarian Neoplasms

Studies at this site

• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — Recruiting now
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
• Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass — Recruiting now
• Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor — Stopped early